News headlines about Masimo (NASDAQ:MASI) have trended somewhat positive on Tuesday, according to Accern. Accern scores the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Masimo earned a coverage optimism score of 0.10 on Accern’s scale. Accern also assigned press coverage about the medical equipment provider an impact score of 46.0599346253408 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the media headlines that may have impacted Accern’s scoring:
- Analysts Expect Masimo Co. (MASI) to Post $0.70 Earnings Per Share (americanbankingnews.com)
- Toshiba partners with Atheer to provide enterprise-grade Augmented Reality (AR) software platform for Toshiba’s new dynaEdge™ AR Smart Glasses (bizjournals.com)
- Masimo announces Cairo University researchers evaluate accuracy, trending of its SpHb during acute bleeding and after fluid resuscitation (pharmabiz.com)
- Masimo announces Cairo University researchers evaluate accuracy … – pharmabiz.com (pharmabiz.com)
- New Study Investigates the Performance of Masimo SpHb® During … – Business Wire India (press release) (businesswireindia.com)
Several equities analysts have recently issued reports on MASI shares. Zacks Investment Research lowered shares of Masimo from a “buy” rating to a “hold” rating in a report on Wednesday, January 3rd. BidaskClub lowered shares of Masimo from a “hold” rating to a “sell” rating in a report on Thursday, December 7th. Barclays started coverage on shares of Masimo in a report on Friday, March 9th. They set an “overweight” rating and a $97.00 target price for the company. Finally, Piper Jaffray Companies reiterated a “hold” rating and set a $91.00 target price on shares of Masimo in a report on Thursday, March 1st. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $101.00.
Masimo (NASDAQ:MASI) last announced its quarterly earnings data on Tuesday, February 27th. The medical equipment provider reported $0.72 earnings per share for the quarter, topping analysts’ consensus estimates of $0.61 by $0.11. Masimo had a net margin of 16.49% and a return on equity of 22.75%. The company had revenue of $225.20 million during the quarter, compared to analyst estimates of $201.54 million. During the same period in the previous year, the business earned $0.46 EPS. The firm’s revenue for the quarter was up 22.9% on a year-over-year basis. equities research analysts anticipate that Masimo will post 2.81 EPS for the current year.
In related news, Director Sanford Fitch sold 2,000 shares of the business’s stock in a transaction that occurred on Thursday, January 25th. The shares were sold at an average price of $90.00, for a total value of $180,000.00. Following the completion of the transaction, the director now directly owns 70,249 shares in the company, valued at approximately $6,322,410. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Yongsam Lee sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $92.95, for a total transaction of $929,500.00. Following the completion of the transaction, the executive vice president now owns 79,000 shares of the company’s stock, valued at $7,343,050. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 24,100 shares of company stock valued at $2,186,340. 13.10% of the stock is owned by company insiders.
TRADEMARK VIOLATION WARNING: “Masimo (MASI) Earns Media Sentiment Score of 0.10” was first posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://stocknewstimes.com/2018/03/21/masimo-masi-earns-media-sentiment-score-of-0-10.html.
Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company’s business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry.
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.